Compare HUBG & VERA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | HUBG | VERA |
|---|---|---|
| Founded | 1971 | 2016 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Oil Refining/Marketing | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.8B | 3.0B |
| IPO Year | 1996 | 2021 |
| Metric | HUBG | VERA |
|---|---|---|
| Price | $51.11 | $38.16 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 12 | 10 |
| Target Price | $42.83 | ★ $81.30 |
| AVG Volume (30 Days) | 720.8K | ★ 2.5M |
| Earning Date | 05-12-2026 | 05-06-2026 |
| Dividend Yield | ★ 1.17% | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ 1.34 | N/A |
| Revenue | ★ $3,946,390,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $2.88 | $472.48 |
| P/E Ratio | $38.32 | ★ N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $32.46 | $19.07 |
| 52 Week High | $53.26 | $56.05 |
| Indicator | HUBG | VERA |
|---|---|---|
| Relative Strength Index (RSI) | 73.96 | 46.21 |
| Support Level | $34.16 | $37.34 |
| Resistance Level | $53.26 | $38.59 |
| Average True Range (ATR) | 1.53 | 2.81 |
| MACD | 0.54 | -0.45 |
| Stochastic Oscillator | 95.13 | 21.33 |
Hub Group ranks among the largest providers of rail intermodal service. Approximately 60% of consolidated revenue comes from Hub's intermodal and transportation solutions division. ITS includes its flagship intermodal operations, which use the Class I rail carriers for the underlying line-haul movement of containers, as well as its dedicated truckload shipping unit. Hub's logistics segment includes its asset-light truck brokerage operations along with its outsourced transportation management, warehousing and fulfillment, and heavy-goods final mile delivery offerings. Hub often makes tuck-in acquisitions that expand its brokerage, last-mile, and dedicated offerings.
Vera Therapeutics Inc is a clinical stage biotechnology company. It is focused on developing and commercializing transformative treatments for patients with serious immunological diseases. The company's product candidate is atacicept, a fusion protein self-administered as a subcutaneous injection once weekly that blocks both B lymphocyte stimulator and a proliferation-inducing ligand, which stimulate B cells and plasma cells to produce autoantibodies contributing to certain autoimmune diseases.